StockWatch
·
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Quarterly ResultAug 13, 2026, 04:47 PM

Nuwellis Q2 Net Sales $2.0M (+14%); Gross Margin 76%

AI Summary

Nuwellis, Inc. reported strong financial results for the second quarter of 2026, with net sales increasing 14% year-over-year to $2.0 million and gross margin significantly improving to 76%. The company also reduced its net loss to $4.8 million from $12.6 million in the prior-year quarter. Strategic highlights include progress on Aquadex label expansion, the appointment of a new CEO, and successful capital raises totaling $12.7 million, extending its cash runway through Q2 2027.

Key Highlights

  • Net sales for Q2 2026 were $2.0 million, a 14% increase year-over-year.
  • Gross margin improved to 76% in Q2 2026, up from 56% in the prior-year quarter.
  • Net loss for Q2 2026 was $4.8 million, compared to $12.6 million in Q2 2025.
  • Sold nine consoles in Q2 2026, compared to three in Q2 2025.
  • Raised $6.0 million in gross proceeds in June, and an additional $6.7 million post-Q2.
  • Cash and cash equivalents were $3.9 million as of June 30, 2026.
  • Advanced Aquadex label expansion for patients weighing 5 kilograms or more.
  • Mike McCormick appointed President and CEO, effective June 30, 2026.